“RemedyRePack Losartan 50mg Tablets Recall: AZIDO Impurity Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34972-remedyrepack-losartan-50mg-tablets-recall-azido-impurity-risk. Based on FDA recall #D-0788-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0788-2022%22&limit=1).
The FDA announced on April 6, 2022, that RemedyRePack Inc. is recalling Losartan Potassium 50 mg tablets due to azido impurity levels exceeding acceptable limits. The agency classified the recall as Class II.
How to tell if you have it
Brand: RemedyRePack
Product: Losartan Potassium 50 mg Tablet
NDC# 70518-3282-1 (30-count blister card)
NDC# 70518-3282-0 (60-count blister card)
Lot # B1467803-120621, exp. date 06/30/2022
Lot # J0585793-121721, exp. date 12/31/2022
The hazard
The recall addresses CGMP deviations where azido impurity levels were observed to be above acceptable limits.
Context
GovInfoNow's records show RemedyRePack Inc. has 35 other recalls on record since February 18, 2015. Recent brand recalls include Clindamycin Capsules recalled on April 22, 2025, and March 24, 2025, due to CGMP deviations, as well as Carvedilol Tablets recalled on January 24, 2025, for N-Nitroso impurity risk. Other recent recalls of similar products include Amneal traMADol 50mg Tablets (March 19, 2026), Zydus Mirabegron 25mg Tablets (August 5, 2026), and Macleods Olanzapine Tablets 5mg (August 27, 2026).
How to tell if you have this one
Check for 30-count or 60-count blister packs labeled with NDC numbers 70518-3282-1 or 70518-3282-0. The lot numbers and expiration dates listed in the recall are also key identifiers.
Brand
RemedyRePack
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Your Medication
Look for the specific blister packs with NDC numbers 70518-3282-1 or 70518-3282-0.
Where it went and when
Where it was distributed
Distributed in Alaska and Pennsylvania.
Listed by the agency
Not listed
FDA distribution: “Product was distributed to customers in AK and PA.” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Alaska, Pennsylvania.
Recall timeline
FDA terminated this recall 51 days after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0788-2022 (April 6, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0788-2022 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.